Form 4: Solid Biosciences Director Sells Shares Under 10b5-1 Plan

Solid Biosciences Inc. Director Ilan Ganot sold 3,278 shares of common stock for a weighted average price of $4.12 per share under a pre-arranged trading plan.

Summary

• Ilan Ganot, a Director of Solid Biosciences Inc. (SLDB), sold 3,278 shares of common stock.
• The transaction occurred on November 10, 2025.
• The shares were sold at a weighted average price of $4.12, with individual transactions ranging from $4.11 to $4.12.
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan, indicating it was pre-arranged.
• Following the transaction, Mr. Ganot directly owns 95,412 shares and indirectly owns 14,839 shares through his wife and 19,394 shares through the Ilan Ganot 2017 Irrevocable Trust.

Sentiment

Score: 5

Explanation: The sale by a director, while under a pre-arranged 10b5-1 plan, is a neutral event. It does not necessarily reflect a change in the director's outlook on the company's future, but it is also not a vote of confidence through buying.

Negatives

• Director Ilan Ganot sold 3,278 shares of Solid Biosciences Inc. common stock.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Ilan Ganot's beneficial ownership includes 14,839 shares held by his wife and 19,394 shares held by the Ilan Ganot 2017 Irrevocable Trust, where Adam Ganot and Annie Ganot are trustees.

Stakeholder Impact

• Shareholders may interpret the director's sale, even if pre-planned, as a slight negative signal, potentially impacting short-term sentiment, though the 10b5-1 plan mitigates this.

Key Dates

Recommendation

The Form 4 reports a routine, pre-planned sale by a director, not indicating any new material information about the company's prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Solid Biosciences, SLDB, Ilan Ganot, Director, Insider Sale, Form 4, Common Stock, Rule 10b5-1